Standard BioTools Inc 2024年度报告

FORM10-K STANDARD BIOTOOLS INC. shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter)during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See thedefinitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standardsprovided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.Yes☒No☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error topreviously issued financial statements.☐Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ As of June 28, 2024, the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately $433.1million based on the closing sale price on that date. Shares of common stock held by each executive officer and director and by each other person whomay be deemed to be an affiliate of the Registrant have been excluded from this computation. The determination of affiliate status for this purpose is not necessarily a conclusive determination for otherpurposes. As of March 2, 2025, there were378,986,362shares of the registrant’s common stock outstanding. DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s proxy statement in connection with the registrant’s annual meeting of stockholders, scheduled to be held in June 2025, are incorporated by reference in Part III of thisreport. Except as expressly incorporated by reference, such proxy statement shall not be deemed to be part of this report. STANDARD BIOTOOLS INC.FISCAL YEAR 2024FORM 10-KANNUAL REPORT ITEM 1.BusinessITEM 1A.Risk FactorsITEM 1B.Unresolved Staff CommentsITEM 1C.CybersecurityITEM 2.PropertiesITEM 3.Legal ProceedingsITEM 4.Mine Safety Disclosures PART II ITEM 5.Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of EquitySecurities55ITEM 6.[Reserved]56ITEM 7.Management's Discussion and Analysis of Financial Condition and Results of Operations57ITEM 7A.Quantitative and Qualitative Disclosures about Market Risk69ITEM 8.Financial Statements and Supplementary Data70ITEM 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosures113ITEM 9A.Controls and Procedures113ITEM 9B.Other Information114ITEM 9CDisclosures Regarding Foreign Jurisdictions that Prevent Inspections114 PART III ITEM 10.Directors, Executive Officers and Corporate Governance115ITEM 11.Executive Compensation115ITEM 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters115ITEM 13.Certain Relationships and Related Transactions, and Director Independence115ITEM 14.Principal Accounting Fees and Services115 PART IV ITEM 15.Exhibits, Financial Statement Schedules116ITEM 16.Form 10-K Summary116 INDEX TO EXHIBITS117SIGNATURES125 Special Note Regarding Forward-looking Statements and Industry Data This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on our management’s beliefsand assumptions and on information currently available to our management. The forward-looking statements are containedprincipally in the sections entitled “Business,” “Risk Factors,” and “Management’s Discussion and Analysis of Financial Conditionand Results of Operations.” Forward-looking statements include information concerning our possible or assumed future cash f